ClinicalTrials.gg
WithdrawnNCT04577820Updated Nov 1, 2021

Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)

A Phase 3 interventional study of garetosmab in Fibrodyplasia Ossificans Progressiva (FOP) and Heterotopic Ossification (HO), sponsored by Regeneron Pharmaceuticals. Withdrawn. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-11-01.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Phase 2 Study R2477-FOP-1940 has been withdrawn and the next phase of the development program is being planned

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The primary safety objective of the study is to assess the safety and tolerability of garetosmab in Japanese male and female adult patients with FOP.

The primary efficacy objective of the study is to assess the effect of garetosmab on Heterotopic ossification (HO) in Japanese adult patients with FOP, as determined by the number of new heterotopic bone lesions identified by computed tomography (CT).

02

Conditions studied

  • Fibrodyplasia Ossificans Progressiva (FOP)
  • Heterotopic Ossification (HO)
03

In context

Ossification, Heterotopic

38 studies on the registry are indexed under Ossification, Heterotopic; 7 are open to participants now.

Browse Ossification, Heterotopic studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Clinical diagnosis of FOP (based on findings of congenital malformation of the great toes, episodic soft tissue swelling, and/or progressive HO)
  • Confirmation of FOP diagnosis with documentation of any Type I activin A receptor (ACVR1) mutation
  • FOP disease activity, as defined in the protocol, within 1 year of screening visit
  • Willing and able to undergo PET and CT imaging procedures and other procedures as defined in this study
  • Able to understand and complete study-related questionnaires and diaries (assistance from caregivers is allowed)

Key Exclusion Criteria:

  • Patient has significant concomitant illness or history of significant illness such as but not limited to cardiac, renal, rheumatologic, neurologic, psychiatric, endocrine, metabolic, or lymphatic disease, that in the opinion of the study investigator might confound the results of the study or pose additional risk to the patient by their participation in the study
  • Previous history or diagnosis of cancer
  • Severely impaired renal function defined as estimated \<30 mL/min/1.73 m2 calculated by the Modification of Diet in Renal Disease equation (1 retest is allowed)
  • Uncontrolled diabetes defined as (HbA1c) >9% at screening (1 retest allowed)
  • History of severe respiratory compromise, as defined in protocol
  • Concurrent participation in another interventional clinical study or a non-interventional study with radiographic measures or invasive procedures
  • Pregnant or breastfeeding women

NOTE: Other protocol defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    garetosmab

    Drug: garetosmab

Interventions

  • Repeated doses administered intravenously (IV) every four weeks (Q4W)

    Also known as: REGN2477

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-emergent adverse event (TEAEs)

    Time frame: Through week 28

  2. Number of new HO lesions as assessed by CT

    Time frame: At week 28

Secondary outcomes

  1. Total volume of new HO lesions as assessed by CT

    Time frame: At week 28

  2. Number of new HO lesions as assessed by positron emission tomography (PET)

    Time frame: At week 28

  3. Total lesion activity in new HO lesions as assessed by PET

    Time frame: At week 28

  4. Percent of patients with new HO lesions as assessed by CT

    Time frame: At week 28

  5. Percent of patients with new HO lesions as assessed by PET

    Time frame: At week 28

  6. Percent of patients with investigator-assessed flare-ups

    Time frame: Baseline to week 28

  7. Percent of patients with investigator-assessed flare-ups

    Time frame: Baseline to week 56

  8. Percent of patients with flare-ups assessed by patient e-diary

    Time frame: Baseline to week 28

  9. Percent of patients with flare-ups assessed by patient e-diary

    Time frame: Baseline to week 56

  10. Number of new HO lesions as assessed by CT

    Time frame: At week 56

  11. Total volume of new HO lesions as assessed by CT

    Time frame: At week 56

  12. Percent of patients with new HO lesions as assessed by CT

    Time frame: At week 56

  13. Number of new HO lesions as assessed by PET

    Time frame: At week 56

  14. Total lesion activity in new HO lesions as assessed by PET

    Time frame: At week 56

  15. Percent of patients with new HO lesions as assessed by PET

    Time frame: At week 56

  16. Change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET

    Time frame: Baseline and week 28

  17. Change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET

    Time frame: Baseline and week 56

  18. Percent change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET

    Time frame: Baseline and week 28

  19. Percent change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET

    Time frame: Baseline and week 56

  20. Change in total lesion activity by PET

    Time frame: Baseline and week 28

  21. Change in total lesion activity by PET

    Time frame: Baseline and week 56

  22. Percent change in total lesion activity by PET

    Time frame: Baseline and week 28

  23. Percent change in total lesion activity by PET

    Time frame: Baseline and week 56

  24. Change in the total volume of HO lesions as assessed by CT

    Time frame: Baseline and week 28

  25. Change in the total volume of HO lesions as assessed by CT

    Time frame: Baseline and week 56

  26. Percent change in the total volume of HO lesions as assessed by CT

    Time frame: Baseline and week 28

  27. Percent change in the total volume of HO lesions as assessed by CT

    Time frame: Baseline and week 56

  28. Change in number of HO lesions as assessed by PET

    HO lesions defined as target and new lesions relative to baseline.

    Time frame: Baseline and week 28

  29. Change in number of HO lesions as assessed by PET

    Defined above

    Time frame: Baseline and week 56

  30. Change in the number of HO lesions detectable by CT

    Defined above

    Time frame: Baseline and week 28

  31. Change in the number of HO lesions detectable by CT

    Defined above

    Time frame: Baseline and week 56

  32. Time-weighted average (standardized area under curve [AUC]) change in daily pain due to FOP, as measured using the daily numeric rating scale (NRS)

    The NRS is a categorical rating scale used by patients to rate their pain associated with FOP. Patients will be asked to rate their pain on a scale that ranges from "0" (no pain) to "10" (worst possible pain).

    Time frame: Baseline through week 28

  33. Time-weighted average (standardized AUC) change in daily pain due to FOP, as measured using the daily NRS

    Time frame: Baseline through week 56

  34. Total dosage of glucocorticoids use

    Time frame: Through week 56

  35. Incidence and severity of TEAEs

    Time frame: Through week 56

  36. Concentration of total activin A in serum over time

    Time frame: Through week 56

  37. Pharmacokinetic (Pk) Profile - concentrations of garetosmab in serum over time

    Time frame: Through week 56

  38. Immunogenicity as measured by Anti-drug antibodies (ADA) to garetosmab over time

    Time frame: Through week 28

  39. Percent change from baseline in biomarkers of bone formation levels in serum

    Time frame: Through week 28

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2021; primary completion for Mar 2022, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2020
First posted
Oct 8, 2020
StartEst.
Oct 13, 2021
Primary completionEst.
Mar 1, 2022
CompletionEst.
Oct 8, 2022
Last update
Nov 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04577820
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Oct 13, 2021 (estimated)
Primary completion
Mar 1, 2022 (estimated)
Completion
Oct 8, 2022 (estimated)
Last update
Nov 1, 2021

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Garetosmab

Start the discussion